Browse RGS1

Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Peripheral membrane protein Cytoplasmic side Cytoplasm, cytosol
Domain PF00615 Regulator of G protein signaling domain
Function

Regulates G protein-coupled receptor signaling cascades, including signaling downstream of the N-formylpeptide chemoattractant receptors and leukotriene receptors (PubMed:10480894). Inhibits B cell chemotaxis toward CXCL12 (By similarity). Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form (PubMed:10480894, PubMed:18434541).

> Gene Ontology
 
Biological Process GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway
GO:0061737 leukotriene signaling pathway
Molecular Function GO:0001965 G-protein alpha-subunit binding
GO:0005096 GTPase activator activity
GO:0005516 calmodulin binding
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0009898 cytoplasmic side of plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RGS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RGS1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23319273Prostate CarcinomaInhibit immunityStudies revealed that the levels of expression of genes responsible for T-cell proliferation (C-FOS, C-JUN and DUSP1) and cellular migration (RGS1) were greater in Tregs from mCRPC patients as compared to values observed in healthy donors.
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RGS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RGS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0350.958
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1710.948
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0440.979
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4620.456
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5710.727
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3160.889
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2170.751
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4010.816
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3150.84
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8250.602
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.520.826
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1450.606
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RGS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RGS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RGS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RGS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RGS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RGS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RGS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRGS1
Nameregulator of G-protein signaling 1
Aliases 1R20; IR20; BL34; IER1; regulator of G-protein signalling 1; HEL-S-87; B-cell activation protein BL34; early ......
Chromosomal Location1q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RGS1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.